GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Opthea Ltd (ASX:OPT) » Definitions » Buyback Yield %

Opthea (ASX:OPT) Buyback Yield % : -28.92 (As of Apr. 28, 2025)


View and export this data going back to 1991. Start your Free Trial

What is Opthea Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Opthea's current buyback yield was -28.92%.


Opthea Buyback Yield % Historical Data

The historical data trend for Opthea's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Opthea Buyback Yield % Chart

Opthea Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Buyback Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7.52 -29.44 - -47.45 -62.61

Opthea Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -28.38 -47.45 -21.13 -62.61 -21.42

Competitive Comparison of Opthea's Buyback Yield %

For the Biotechnology subindustry, Opthea's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Opthea's Buyback Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Opthea's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Opthea's Buyback Yield % falls into.


;
;

Opthea Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Opthea's Buyback Yield for the fiscal year that ended in Jun. 2024 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 239.18) / 382.01345
=-62.61%

Opthea's annualized Buyback Yield for the quarter that ended in Dec. 2024 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0 + 213.647) / 997.31331
=-21.42%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .


Opthea Buyback Yield % Related Terms

Thank you for viewing the detailed overview of Opthea's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Opthea Business Description

Traded in Other Exchanges
Address
650 Chapel Street, Level 4, Suite 0403, South Yarra, VIC, AUS, 3141
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.